International African Inventors Museum IAI Museum Homeemail
Featured Inventors
Mark E. Dean
Patricia Bath
Carlton L. Gyles
Issa Odidi
Joseph E. Dadson
Juliet M. Daniel
Warren Salmon
Jude Igwemezie
Charles Drew
William Peyton Hubbard
Elijah McCoy
Dr. Issa Odidi

Dr. Issa Odidi is Founder, Chairman of the Board, Chief Executive Officer, Co-Chief Scientific Officer and Chair of the Scientific Advisory Board of IntelliPharmaCeutics. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine, California, U.S.A.

Professor Issa Odidi received his B.Sc. degree in Pharmacy, from Ahmadu Bello University in Nigeria, his M.Sc., Pharmaceutical Technology and Ph.D Pharmaceutics degrees from the University of London, England.

Dr. Amina Odidi is a Founder, Director, President, Chief Operating Officer and Co-Chief Scientific Officer of IntelliPharmaCeutics.

Dr. Amina Odidi received her B.Sc. degree in Pharmacy, from Ahmadu Bello University, and her M.Sc., Biopharmaceutics and Ph.D Pharmaceutics degrees from the University of London, England.

The Chief Scientists at IntelliPharmaCeutics, Dr. Issa Odidi and Dr. Amina Odidi, are the inventors of each of the diverse core drug delivery technologies which the company now successfully exploits. They were also directly responsible for the design, development and advancement to production scale of each of the ten FDA-approved and commercially successful drugs and dosage strengths now on sale in the United States.

IntelliPharmaCeutics is a leading edge designer and developer of controlled release drug products. Backed by the Company's breakthrough HYPERMATRIX TM drug delivery technology, its world class team of R&D scientists have enjoyed unprecedented success in developing blockbuster controlled release drugs for their clients.

IntelliPharmaCeutics' track record in designing and developing controlled release drug products for its clients is second to none. Of the approximately 15 bio-equivalent controlled release products in the U.S. market today, 7 of them were designed and developed by the Company's scientists and now enjoy strong sales in the demanding U.S. market.